Document is current

Article History

Accepted: 30 June 2025

First Online: 31 August 2025

Declarations

:

: This study was sponsored by UCB. This article, and its associated graphical abstract, were based on the original studies BE VIVID (NCT03370133), BE SURE (NCT03412747), BE BRIGHT (NCT03598790), and BE RADIANT (NCT03536884), sponsored by UCB. Support for third-party writing assistance for this article and its associated graphical abstract, provided by Michael Haycox, PhD, Alexa Holland, MSc, and Ria Gill, BSc, Costello Medical, UK, was funded by UCB in accordance with Good Publication Practice (GPP 2022) guidelines ().

: Joseph F. Merola: consultant and/or investigator for AbbVie, Amgen, AstraZeneca, Biogen, Bristol Myers Squibb, Boehringer Ingelheim, Dermavant, Eli Lilly and Company, Incyte, Janssen, LEO Pharma, MoonLake Immunotherapeutics, Novartis, Pfizer, Sanofi-Regeneron, Sun Pharma, and UCB. Richard B. Warren: consulting fees from AbbVie, Almirall, Amgen, Arena, Astellas, Avillion, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, DICE Therapeutics, Eli Lilly and Company, GSK, Janssen, LEO Pharma, Meiji Pharma, Novartis, Pfizer, RAPT Therapeutics, Sanofi, Sun Pharma, UCB, and Union; research grants to his institution from AbbVie, Almirall, Amgen, Celgene, Eli Lilly and Company, Janssen, LEO Pharma, Novartis, Pfizer, and UCB; honoraria from AbbVie, Almirall, Bristol Myers Squibb, Eli Lilly and Company, Galderma, Janssen, and Novartis. Diamant Thaçi: investigator and/or consultant/advisor for AbbVie, Almirall, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celltrion, Eli Lilly and Company, Galderma, Johnson & Johnson, Kyowa Kirin, LEO Pharma, L’Oreal, New Bridge, Novartis, Pfizer, Regeneron, Samsung, Sanofi, Takeda, Target-RWE, UCB, and Vichy; received grants from AbbVie, LEO Pharma, and Novartis. Kenneth B. Gordon: received consulting fees from AbbVie, Almirall, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Dermira, Eli Lilly and Company, Janssen, Novartis, Pfizer, Sun Pharma, and UCB; research support from AbbVie, Bristol Myers Squibb, Celgene, Eli Lilly and Company, Janssen, Novartis, and UCB. Emi Nishida: AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly and Company, Janssen, Kyowa Kirin, LEO Pharma, Maruho, Novartis, Pfizer, Regeneron, Sanofi, Sun Pharma, Taiho, Torii, and UCB. Bruce Strober: consultant (honoraria) for AbbVie, Alumis, Almirall, Amgen, Arcutis, Boehringer Ingelheim, Bristol Myers Squibb, Capital One, CorEvitas, Dermavant, Janssen, LEO Pharma, Eli Lilly and Company, Maruho, Oruka, Meiji Seika Pharma, Protagonist, Takeda, Novartis, Pfizer, UCB, Rapt, Regeneron, Sanofi-Genzyme, and Union Therapeutics; stock options from Connect Biopharma and Mindera Health; speaker for AbbVie, Arcutis, Dermavant, Eli Lilly and Company, Incyte, Janssen, Regeneron, and Sanofi Genzyme; scientific co-director (consulting fee): CorEvitas Psoriasis Registry; investigator for CorEvitas Psoriasis Registry; editor-in-chief (honorarium): Journal of Psoriasis and Psoriatic Arthritis. Curdin Conrad: consultant and/or principal investigator in clinical trials for AbbVie, Actelion, Almirall, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly and Company, Galderma, Incyte, Johnson & Johnson, LEO Pharma, MSD, Novartis, Pfizer, Samsung, Sanofi, Takeda, and UCB. Sarah Kavanagh: consultant for Aclipse Therapeutics, Aliada Therapeutics, Allay Therapeutics, Autobahn Therapeutics, Cognition Therapeutics, Colorado Prevention Center, Karuna Therapeutics, Kisbee Therapeutics, LB Pharmaceuticals, Nesos, Novartis, Onward Medical, PharPoint Research, Summit Analytical, Tonix Pharmaceuticals, Tornado Therapeutics, UCB, Whitsell Innovations, Worldwide Clinical Trials, and Zosano Pharma. José Manuel López Pinto, Bengt Hoepken: employees and shareholders of UCB. Paolo Gisondi: consultant for AbbVie, Abiogen, Almirall, Celgene, Eli Lilly and Company, Janssen, LEO Pharma, Merck, MSD, Novartis, Otsuka, Pfizer, Pierre Fabre, Sanofi, and UCB.

: Studies were conducted in accordance with the principles of the Declaration of Helsinki and approved by an independent review board and independent ethics committee.

: All participants provided informed written consent documented in accordance with local regulations.

: All the results presented in this article are in aggregate form, and no personally identifiable information was used for this study.

: Underlying data from this article may be requested by qualified researchers 6 months after product approval in the USA and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents, which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of these data, proposals need to be approved by an independent review panel at and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password-protected portal.

: Not applicable.

: Substantial contributions to study conception and design: JFM, RBW, DT, KBG, EN, BS, CC, SK, JMLP, BH, PG; substantial contributions to analysis and interpretation of the data: JFM, RBW, DT, KBG, EN, BS, CC, SK, JMLP, BH, PG; drafting the article or revising it critically for important intellectual content: JFM, RBW, DT, KBG, EN, BS, CC, SK, JMLP, BH, PG; final approval of the version of the article to be published: JFM, RBW, DT, KBG, EN, BS, CC, SK, JMLP, BH, PG.